Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors

US8637500B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Jennifer R. Allen · Newbury Park, US
• Ning Chen · Thousand Oaks, US
• James R. Falsey · Moorpark, US
• Michael J. Frohn · Thousand Oaks, US
• Paul E. Harrington · Camarillo, US
• Essa Hu Harrington · Camarillo, US
• Matthew R. Kaller · Ventura, US
• Roxanne Kunz · Santa Monica, US
• Thomas Nguyen · Newbury Park, US
• Alexander J. Pickrell · Westlake Village, US
• Andreas Reichelt · Moorpark, US
• Shannon Rumfelt · Camarillo, US
• Robert M. Rzasa · Ventura, US
• Kelvin Sham · Thousand Oaks, US
• Aaron C. Siegmund · Ventura, US
• Guomin Yao · Mililani, US

Key dates

• Filing date: Dec 16, 2009
• Grant date: Jan 28, 2014
• Expiry date: Nov 27, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pyridine and pyrimidine compounds:or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification;or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; andor a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.